___

• Alberto, A., Gabizon, M. D. (2001). Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest, 19, 424.
• Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., Quezado, M., Lowy, I., Yellin, M., Rosenberg, S. A., Yang, J. C. (2006). Enterocolitis in patients with cancer after antibody blockade of cytotoxic T lymphocyte–associated antigen 4. J Clin Oncol, 24, 283-289.
• Buggins, A. G., Mufti, G. J., Salisbury, J., Codd, J., Westwood, N., Arno, M., Fishlock, K., Pagliuca, A., Devereux, S. (2002). Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood, 100, 1715-1720.
• Chamuleau, M. E., van de Loosdrecht, A. A., Huijgens, P. C. (2010). Monoclonal antibody therapy in haematological malignancies. Curr Clin Pharmacol, 5,148-159.
• de Boissieu, P., Kanagaratnam, L., Mahmoudi, R., Morel, A., Drame, M., Trenque, T. (2017). Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review. Eur J Clin Pharmacol, 73, 517- 523.
• Demirkazık, A., Özal, G. (2010). Prostat kanserinde hedefe yönelik tedavinin yeri. Üroonkoloji Bülteni, 2, 64-68.
• Doğan, L. A., Güç, D. (2004). Sinyal iletimi mekanizmaları ve kanser. Hacettepe Tıp Dergisi, 35, 34-42.
• Doğan, Ö. O., Kurtuluş, B., Çevik, P. (2009). Bifosfonat kullanan hastalarda oral cerrahi uygulamalarda karşılaşılabilecek sorunlar ve tedavisi. Istanbul Univ Dishekim Fak Derg, 43, 113-122.
• Dumlu, A., Varol, A., Yalçınkaya, Ş., Özbayrak, S. (2011). Oral ve intravenöz bifosfonat kaynaklı çene osteonekrozu. Türkiye Klinikleri J Dental Sci, 17, 70-75.
• Elloumi, J., Jellali, K., Jemel, I., Aifa, S. (2012). Monoclonal antibodies as cancer therapeutics. Recent Pat Biotechnol, 6, 45-56.
• Erdoğan, M. A. (2019). Cancer, drug targeting and targeted therapies. Asian Journal of Emerging Research, 1(2), 69-81.
• Eskiizmir, G., Ermertcan, A. T., Yapici, K. (2017). Nanomaterials: promising structures for the management of oral cancer. 1st Ed., Andronescu E, Grumezesc A. (Eds), Nanostructures for Oral Medicine, Elsevier, Philadelphia, United States, pp. 511-544.
• Fizazi, K., Sternberg, C. N., Fitzpatrick, J. M., Watson, R. W., Tabesh, M. (2010). Role of targeted therapy in the treatment of advanced prostate cancer. BJU Int, 105, 748-767.
• Font, R. G., García, M. L., Martínez, J. M. (2008). Osteochemonecrosis of the jaws due to bisphosphonate treatment. Update. Med Oral Patol Oral Cir Bucal, 13, E318-24.
• Fukumura, D., Jain, R. K. (2007). Tumor microvasculature and microenvironment: targets for antiangiogenesis and normalization. Microvasc Res, 74, 72.
• Greish, K. (2007). Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target, 15, 457.
• Hamid, O. (2004). Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors. J Am Pharm Assoc, 44, 52-58
• Harris, A. L. (2002). Hypoxia- a key regulatory factor in tumour growth, Nat Rev Cancer, 2, 38.
• Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T. M., Dallaire, B. K., Wey, K., Royston, I., D Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., McDonald, D. M. (2000). Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol, 156, 1363.
• Henry, D., von Moos R., Vadhan-Raj, S., Hungria, V., Spencer, A., Hirsh, V., Wang, J., Jun, S., Yeh, H., Dansey, R. (2009). A double blind randomized study of denosumab versus zoledronic acid for the treatment of bone metastasis in patients with advanced cancer. Eur J Cancer, 7(suppl), 11.
• Hodi, F. S., O’Day, S. J., McDermott, D. F., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 363, 711–723.
• Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., Kabbinavar, F. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350, 2335–2342.
• Jain, R. K. (2003). Molecular regulation of vessel maturation, Nat Med, 9, 685.
• Kaş, H. S., Eldem, T. (2002). Kontrollü salım sistemlerinin hedeflendirilmesi. Gürsoy, A. (Editor), Kontrollü salım sistemleri, Kontrollü Salım Sistemleri Derneği Yayını, İstanbul, pp. 308.
• Keating, M. J., Cazin, B., Coutre, S., Birhiray, R., Kovacsovics, T., Langer, W., Leber, B., Maughan, T., Rai, K., Tjønnfjord, G., Bekradda, M., Itzhaki, M., Hérait, P. (2002). Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol, 20, 205–213.
• Khan, A. A., Morrison, A., Hanley, D. A., et al. (2015). Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res, 30, 3-23.
• Khan, A. A., Morrison, A., Kendler, D. L., et al. (2017). Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ. J Clin Densitom, 20, 8-24.
• Kopecek, J., Kopeckova, P., Minko, T., Lu, Z. R., Peterson, C. M. (2001). Water soluble polymers in tumor targeted delivery, J Control Release, 74, 147.
• Kraft, A., Weindel, K., Ochs, A., Marth, C., Zmija, J., Schumacher, P., Unger, C., Marmé, D., Gastl, G. (1999). Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer, 85, 178-187.
• Lammers, T., Hennink, W. E., Storm, G. (2008). Tumour targeted nanomedicines: principles and practice, Brit J Cancer, 99, 392.
• Leaf, C. (2004). Why we are losing the war on cancer (and how to win it), Fortune, 149, 84.
• Los, M., Roodhart, J. M., Voest, E. E. (2007). Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. The Oncologist, 12, 443-450.
• Macfarlane, R. J., Chi, K. N. (2010). Nover targeted therapies for prostate cancer. Urol Clin N Am, 37, 105-119.
• Davis, T., Levy, R. (1997). IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood, 90, 2188-2195.
• Marx, R. E. (2003). Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg, 61, 1115-1117.
• Marx, R. E. (2011). Oral and intravenous bisphosphonate–induced osteonecrosis of the jaws: history, etiology, prevention, and treatment. 2nd edition, Quintessence.
• Matsumura, Y., Maeda, H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res, 46, 6387.
• Nicolatou-Galitis, O., Schiødt, M., Mendes, R.A., Ripamonti, C., Hope, S., Drudge-Coates, L., Niepel, D., Van den Wyngaert, T. (2019). Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol, 127,117-135.
• Özbayrak, S., Pekiner, F. (2016). Ağız kanserleri, erken tanı bakımından diş hekimliği, Quintessence Yayıncılık, İstanbul.
• Özbayrak, S. (2017). Oral mukoza ve hastalıkları. 3. Baskı, Quintessence Yayıncılık, İstanbul.
• Pekiner, F. N. (2014). Bifosfonatlara bağlı olarak gelişen osteonekroz. Dental Klinik Dergisi, 8, 30-35.
• Piccaluga, P. P., Agostinelli, C., Righi, S., Zinzani, P. L., Pileri, S. A. (2007). Expression of CD52 in peripheral T-cell lymphoma. Haematologica, 92, 566-567.
• Press, M. F., Pike, M. C., Chazin, V. R., Hung, G., Udove, J. A., Markowicz, M., Danyluk, J., Godolphin, W., Sliwkowski, M., Akita, R., et al. (1993). HER-2/neu expression in nodenegative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res, 53, 4960-4970.
• Ratzinger, G., Reagan, J. L., Heller, G., Busam, K. J., Young, J. W. (2003). Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood, 101, 1422- 1429.
• Ravdin, P. M., Chamness, G. C. (1995). The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm aborat development of other macromolecular markers-a review. Gene, 159, 19-27.
• Reff, M. E., Carner, K., Chambers, K. S., Chinn, P. C., Leonard, J. E., Raab, R., Newman, R. A., Hanna, N., Anderson, D. R. (1994). Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 83, 435–445.
• Riechmann, L., Clark, M., Waldmann, H., Winter, G. (1988). Reshaping human antibodies for therapy. Nature, 332, 323-327.
• Rosella, D., Papi, P., Giardino, R., Cicalini, E., Piccoli, L., Pompa, G. (2016). Medication-related osteonecrosis of the jaw: clinical and practical guidelines. J Int Soc Prevent Communit Dent 6,97-104.
• Ruggiero, S. L., Dodson, T. B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., O’Ryan, F. (2014). American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg, 72, 1938–1956.
• Seshadri, R., Firgaira, F. A., Horsfall, D. J., McCaul, K., Setlur, V., Kitchen, P. (1993). Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol, 11, 1936-1942.
• Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, 783-792.
• Şakalar, Ç., İzgi, K., Canatan, H. (2013). Kanser immün terapi ve monoklonal antikorlar. F.Ü. Sağ Bil Tıp Derg, 27(2), 105-110.
• Tatum, J. L., Kelloff, G. J., Gillies, R. J., Arbeit, J. M., Brown, J. M., Chao, K. S., Chapman, J. D., Eckelman, W. C., Fyles, A. W., Giaccia, A. J., Hill, R. P., Koch, C. J., Krishna, M. C., Krohn, K. A. (2006). Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol, 82, 699.
• Taylor, K. H., Middlefell, L. S., Mizen, K. D. (2010). Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg, 48, 221-223. Waldmann, T. A. (2003). Immunotherapy: past, present and future. Nature Medicine, 9, 269–277.
• Wu, J., Akaike, T., Maeda, H. (1998). Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase ınhibitor, and a nitric oxide scavenger. Cancer Res, 58.
• Yoneda, T., Hagino, H., Sugimoto, T., Ohta, H., Takahashi, S., Soen, S., Taguchi, A., Nagata, T., Urade, M., Shibahara, T., Toyosawa, S. (2017). J Bone Miner Metab, 35, 6-19.
• Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., Jain, R. K. (1995). Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res, 55, 3752.